Biosimilars | Specialty

The OncLive Biosimilars condition center page is a comprehensive resource for clinical news and expert insights on currently available and investigational biosimilars for reference drugs such as trastuzumab, rituximab, bevacizumab, and more. This page features news articles, interviews in written and video format, and podcasts that focus on updates with biosimilars and ongoing research with these types of agents.

Dr. Verma Discusses Biosimilars in the Oncology Sphere

March 27th 2018

Sunil Verma, MD, professor and head of the Department of Oncology at the University of Calgary, medical director of the Tom Baker Cancer Centre, discusses biosimilars in the oncology sphere.

Trastuzumab Biosimilar Approaches European Approval

March 23rd 2018

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for the marketing authorization of ABP 980, a biosimilar to trastuzumab.

Brufsky Discusses Biosimilar Breakthroughs and Challenges

March 21st 2018

Adam Brufsky, MD, PhD, comments the FDA approval of MYL-1401O and discusses the adoption of biosimilars in oncology.

Expert Shares Excitement Over Biosimilars in Oncology

March 20th 2018

Sunil Verma, MD, shares his insight on the approval of MYL-1401O, as well as his excitement for the future development of biosimilars across oncology.

Dr. Brufsky on Challenges Facing Biosimilars in Breast Cancer

March 16th 2018

Adam M. Brufsky, MD, PhD, professor of medicine, associate chief, Division of Hematology/Oncology, co-director, Comprehensive Breast Cancer Center, associate director, Clinical Investigation, University of Pittsburgh, discusses challenges facing biosimilars for the treatment of patients with breast cancer.

Dr. Verma on Incorporating Biosimilars Into Practice

March 13th 2018

Sunil Verma, MD, professor and head of the Department of Oncology at the University of Calgary, medical director of the Tom Baker Cancer Centre, discusses incorporating biosimilars in oncology practice.

Dr. Rugo Discusses Advancements With Biosimilars

March 2nd 2018

Hope Rugo, MD, professor of medicine, director of the Breast Oncology Clinical Trials Program, UCSF Helen Diller Family Comprehensive Cancer Center, discusses recent advancements with biosimilars.

Trastuzumab Biosimilar Demonstrates Equivalence in HER2+ Breast Cancer

January 31st 2018

The trastuzumab (Herceptin) biosimilar SB3 induced a rate of breast pathologic complete response similar to trastuzumab in women with HER2-positive breast cancer, according to results from a phase III study of 800 patients.

Rituximab Biosimilar Succeeds in Phase III Follicular Lymphoma Trial

January 25th 2018

PF-05280586, a biosimilar for rituximab (Rituxan/MabThera), delivered positive top-line results in the phase III REFLECTIONS B3281006 follicular lymphoma trial.

Emerging Therapies for Follicular Lymphoma

January 23rd 2018

FL: Updated Data for Immunomodulatory Approaches

January 23rd 2018

Immunomodulatory Therapy for FL: The R-Squared Regimen

January 23rd 2018

Further Considerations for Relapsed/Refractory FL

January 23rd 2018

Treatment Approaches to Relapsed Refractory FL

January 23rd 2018

Optimizing Frontline Therapy and Maintenance in FL

January 23rd 2018

Frontline Treatment Approaches to Follicular Lymphoma

January 23rd 2018

FL: Monitoring to Initiate Therapy and Gauge Response

January 23rd 2018

Risk Stratification and Outcomes in Follicular Lymphoma

January 23rd 2018

Diagnosis and Staging for Follicular Lymphoma

January 23rd 2018

Bevacizumab Biosimilar Approved in Europe

January 19th 2018

The European Commission has approved the bevacizumab biosimilar ABP 215, for the treatment of patients across several tumor types.